Tulosta

Lisätietoa HPV rokotteista

Lisätietoa aiheesta
16.8.2016
Kohdunkaulan, emättimen ja ulkosynnytinten solumuutokset -työryhmä

Terapeuttiset rokotteet

Kirjallisuutta

  1. Clifford GM, Smith JS, Plummer M ym. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73 «PMID: 12556961»PubMed
  2. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC ym. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85 «PMID: 19962185»PubMed
  3. Block SL, Brown DR, Chatterjee A ym. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010;29:95-101 «PMID: 19952863»PubMed
  4. Garland SM, Ault KA, Gall SA ym. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179-88 «PMID: 19935017»PubMed
  5. Wacholder S, Chen BE, Wilcox A ym. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712 «PMID: 20197322»PubMed
  6. Garland SM, Ault KA, Gall SA ym. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179-88 «PMID: 19935017»PubMed
  7. Paavonen J, Naud P, Salmerón J ym. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14 «PMID: 19586656»PubMed
  8. Brown DR, Kjaer SK, Sigurdsson K ym. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35 «PMID: 19236279»PubMed
  9. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25 «PMID: 18653221»PubMed
  10. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007;107:S31-3 «PMID: 18499916»PubMed
  11. Wheeler CM, Kjaer SK, Sigurdsson K ym. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44 «PMID: 19236277»PubMed «PMID: 19236277»PubMed
  12. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013;10:400-10 «PMID: 23736648»PubMed
  13. Szarewski A, Skinner SR, Garland SM ym. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis 2013;208:1391-6 «PMID: 24092907»PubMed
  14. Muñoz N, Manalastas R Jr, Pitisuttithum P ym. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-57 «PMID: 19493565»PubMed
  15. Olsson SE, Villa LL, Costa RL ym. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9 «PMID: 17499406»PubMed
  16. Vesikari T, Van Damme P, Lindblad N ym. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010;29:314-8 «PMID: 19952980»PubMed
  17. Joura EA, Giuliano AR, Iversen OE ym. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23 «PMID: 25693011»PubMed
  18. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84:118-31 «PMID: 19360985»PubMed
  19. Gertig DM, Brotherton JM, Budd AC ym. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227 «PMID: 24148310»PubMed
  20. Baldur-Felskov B, Dehlendorff C, Munk C ym. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106:djt460 «PMID: 24552678»PubMed
  21. Pollock KG, Kavanagh K, Potts A ym. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30 «PMID: 25180766»PubMed
  22. Drolet M, Bénard É, Boily MC ym. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565-80 «PMID: 25744474»PubMed
  23. Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Törnberg S & von Karsa L (eds.). European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Office for Official Publications of the European Union, Luxembourg 2015 saatavana http://bookshop.europa.eu/en/european-guidelines-for-quality-assurance-in-cervical-cancer-screening-pbEW0115451/
  24. WHO. Global Advisory Committee on Vaccine Safety, report of meeting held 11-12 December. Wkly Epidemiol Rec, vol. 89, no. 7, pp. 53-60.
  25. Castellsagué X, Muñoz N, Pitisuttithum P ym. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105:28-37 «PMID: 21629249»PubMed
  26. Schwarz TF, Spaczynski M, Schneider A ym. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-7 «PMID: 19022320»PubMed
  27. Trimble CL, Morrow MP, Kraynyak KA ym. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015;386:2078-88 «PMID: 26386540»PubMed
Käypä hoito -suositukset ovat riippumattomia, tutkimusnäyttöön perustuvia kansallisia hoitosuosituksia. Lue lisää
LINKKIEN TYYPIT JA VÄRIKOODIT
Kirjallisuusviite
Kuva
Linkki toiselle sivustolle
Lisätietoa
Näytönastekatsaus
PDF-tiedosto
PubMed-abstrakti
Taulukko